Disease-Modifying Pharmacotherapies for Osteoarthritis

Osteoarthritis is a multifactorial whole-joint disorder characterised by progressive breakdown of articular cartilage, subchondral bone alterations, synovial inflammation and pain. Traditional approaches have focused on symptom relief through analgesics, non-steroidal anti-inflammatory drugs and lifestyle modification, but none alter the underlying structural pathology. Disease-modifying osteoarthritis drugs (DMOADs) seek to intervene in key pathogenic processes—such as cartilage matrix turnover, bone remodelling and inflammatory signalling—to slow or reverse joint degeneration. Emerging classes include anabolic growth factors that stimulate chondrocyte proliferation and matrix synthesis, selective protease inhibitors that prevent excessive collagen and aggrecan breakdown, and small molecules targeting subchondral bone homeostasis or cellular senescence. Preclinical and early clinical studies have demonstrated proof-of-concept for agents that elicit biphasic extracellular matrix remodelling, reduce biomarkers of cartilage and bone degradation, and preserve joint structure. Despite encouraging biomarker and imaging data, definitive evidence of sustained structural modification and symptom improvement remains limited, underscoring the need for well-designed, phenotype-specific trials.

Research from Nature Portfolio

Recent studies of recombinant human fibroblast growth factor 18 have revealed a multiphasic pattern of cartilage remodelling ex vivo. In diseased human knee cartilage explants, continuous exposure to sprifermin initially enhanced aggrecanase activity, promoting controlled degradation of damaged matrix, followed by a robust increase in type II collagen synthesis and chondrocyte metabolic activity. This biphasic response supports a model in which targeted matrix turnover precedes regenerative deposition, offering mechanistic insight into growth-factor-mediated cartilage repair.

Disease-Modifying Pharmacotherapies for Osteoarthritis publication trend

The graph below shows the total number of articles in disease-modifying pharmacotherapies for osteoarthritis across all publications each year (not limited to Nature Index journals).

Technical terms

Disease-modifying osteoarthritis drug (DMOAD): Agent designed to alter the structural progression of osteoarthritis rather than solely relieve symptoms.

Chondrocyte: Specialized cartilage cell responsible for maintaining and synthesizing the extracellular matrix under physiological and therapeutic stimuli.

Extracellular matrix (ECM): Network of collagen, proteoglycans and other macromolecules that provides mechanical support and resilience to articular cartilage.

Aggrecanase: Enzyme family that cleaves aggrecan, a key cartilage proteoglycan, contributing to early matrix degradation in osteoarthritis.

References

1. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. Journal of Translational Medicine (2017).
2. Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo. Scientific Reports (2020).
3. New Trends in Pharmacological Treatments for Osteoarthritis. Frontiers in Pharmacology (2021).
4. From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside. International Journal of Molecular Sciences (2021).